Investment Thesis
Intellia is a pre-revenue CRISPR therapeutics company with severe cash burn (-$395.9M free cash flow) and negative profitability across all metrics, indicating the company is in early-stage development with substantial execution risk. While the company maintains adequate liquidity ($155.5M cash) relative to current burn rate, the fundamental business model is not yet profitable and depends entirely on successful clinical trial outcomes and regulatory approval.
Strengths
- Strong balance sheet with $671.4M stockholders equity and minimal debt
- Adequate liquidity position with $155.5M cash and 5.08x current ratio providing runway
- Revenue growth of 16.9% YoY demonstrates some commercial traction despite pre-commercial stage
Risks
- Massive operating losses (-$441M) with operating margin of -651.7% indicate unsustainable business model dependent on R&D spending
- Severe negative free cash flow (-$395.9M) will deplete cash reserves within ~4 quarters at current burn rate without additional financing
- Clinical-stage biotech with existential risk tied to regulatory approval and clinical trial success; no approved products generating meaningful revenue
- Negative ROE (-61.5%) and ROA (-49.0%) reflect capital inefficiency and lack of profitability foundation
Key Metrics to Watch
- Operating cash flow trend and cash runway (critical for survival)
- Clinical trial progress and regulatory milestones for lead CRISPR programs
- Revenue growth rate and pipeline advancement toward commercialization
- Dilution from future financing rounds and impact on capital structure
Financial Metrics
Revenue
67.7M
Net Income
-412.7M
EPS (Diluted)
$-3.81
Free Cash Flow
-395.9M
Total Assets
842.1M
Cash
155.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-651.7%
Net Margin
-609.9%
ROE
-61.5%
ROA
-49.0%
FCF Margin
-585.0%
Balance Sheet & Liquidity
Current Ratio
5.08x
Quick Ratio
5.08x
Debt/Equity
0.00x
Debt/Assets
20.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-03T21:26:10.872157 |
Data as of: 2025-12-31 |
Powered by Claude AI